Study on the Short-term Efficacy and Safety of Recombinant Human Thrombopoietin Combined With Immunosuppressant Sequential Eltrombopag Ethanolamine Dry Suspension in the Treatment of SAA/TD-NSAA

NCT ID: NCT07001397

Last Updated: 2025-06-03

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 70 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-06-23
• Study Completion Date: 2027-03-23

Brief Summary

The study included adult patients ≥18 years old with SAA and TD-NSAA who had no HLA-matched sibling donors or were not suitable for first-line allogeneic hematopoietic stem cell transplantation due to age, complications, patient wishes, etc. After admission, they were treated with standard IST combined with rhTPO for at least 28 days. After discharge, the sequential treatment of EPAG-PFOS (with an initial dose of 150mg/d) was continued for 2 months (8 weeks), and the follow-up was conducted until the 6th month (24 weeks). It was compared with the historical cohort previously treated with IST combined with EPAG to explore the short-term efficacy and safety of this treatment regimen.

Conditions

Aplastic Anemias

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

rhTPO+IST+EPAG-pfos

Group Type: ACTIVE_COMPARATOR

EPAG-pfos

Intervention Type: DRUG

The initial dose of EPAG-pfos is 150mg/d orally. The dose is adjusted according to hematological indicators, with a maximum dose of 150mg/d until hematological remission is achieved

Interventions

EPAG-pfos

The initial dose of EPAG-pfos is 150mg/d orally. The dose is adjusted according to hematological indicators, with a maximum dose of 150mg/d until hematological remission is achieved

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age ≥18 years old, gender not limited;

2. Patients diagnosed with aplastic anemia (AA) through blood routine, bone marrow puncture, bone marrow biopsy and excluded examinations, and determined as SAA or TD-NSAA according to the Camitta criteria;

3. Those who have not received treatment with immunosuppressants (such as cyclosporine, tacrolimus, ATG, etc.);

4. The patient has no HLA-matched sibling donor or is not suitable for first-line allogeneic hematopoietic stem cell transplantation due to reasons such as age, complications, or the patient's wishes.

5. Before treatment, the total bilirubin (TBIL) of the patient was less than 1.5 times the upper limit of normal value (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were less than 3 times the ULN, and serum creatinine was less than 1.5 times the ULN.

6. ECOG score ≤2 points;

7. Voluntarily join this study, sign the informed consent form, have good compliance and be willing to cooperate with regular follow-up for therapeutic effect evaluation and side effect monitoring;

Exclusion Criteria

1. Pregnant or lactating patients;

2. Have a history of any arterial or venous thrombosis (including stroke, transient ischemic attack, myocardial infarction, deep vein thrombosis or pulmonary embolism) within half a year before enrollment and have at least two of the following risk factors: Hormone replacement therapy, oral contraceptives (including estrogen), smoking, diabetes, hypercholesterolemia, drug-controlled hypertension, hereditary coagulation disorders;

3. Patients with severe cardiovascular diseases (such as NYHA Cardiac Function Score grade III-IV) within half a year before enrollment, known arrhythmias that increase the risk of thromboembolism such as atrial fibrillation, after coronary stent implantation, angioplasty, and after coronary artery bypass grafting;

4. Combined with malignant tumors that seriously affect survival;

5. Within 2 weeks after the start of the study until the end of the study, continuous drug treatment (including but not limited to aspirin, clopidogrel and/or non-steroidal anti-inflammatory drugs NSAIDs) or anticoagulant treatment that affects platelet function for more than 3 days;

6. Currently, there is a severe or difficult-to-control infection (CTC AE level 2 infection);

7. Bone marrow biopsy within 4 weeks before the administration of the first dose of the study indicates the presence of primary diseases other than SAA that can cause thrombocytopenia (such as primary myelodysplastic syndrome (MDS), congenital bone marrow failure diseases (such as Fanconi anemia, congenital keratosis, etc.) Or accompanied by obvious paroxysmal nocturnal hemoglobinuria (PNH) clones (> 50%) and AA with clinical and biochemical indicators of hemolysis; And the researcher judged that the subject was not suitable to participate in this study.

8. All laboratory or clinical evidence of HIV infection, previous clinical history of hepatitis C, previous hepatitis B infection, or active hepatitis at the time of screening. Laboratory tests during the screening period indicated hepatitis C infection or hepatitis B infection. (Defined as a positive HBsAg test. Additionally, if the HBsAg test is negative but HBcAb is positive, regardless of the status of HBsAb, HBV DNA testing is required. If it is positive, the subject should be excluded.)

9. Chronic liver disease-related AA (hepatitis disease-related AA, liver cirrhosis, etc.);

10. Had received treatment with TPO or TPO receptor agonists (TPO-RAS, including but not limited to eltrombopag, romisetine, avatrombopag, heltrombopag, rutrombopag, etc.) before screening;

11. Suffer from severe autoimmune diseases or immunodeficiency diseases;

12. Suffer from serious mental disorders;

13. Patients who the researchers consider unsuitable to participate in this trial, such as those with any other medical, social or psychological factors that may affect safety or compliance with the research procedures.

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Peking Union Medical College Hospital

OTHER

Sponsor Role: lead

Responsible Party

Bing Han

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Central Contacts

Hanbing

Role: CONTACT

01069155097

Other Identifiers

TPO-2024-016

Identifier Type: -

Identifier Source: org_study_id